The difference in immunogens used for the preparation of VU4H5 (a MUC1 60-mer peptide conjugated to bovine serum albumin (BSA)) and VU11E2 (ZR75-1 breast cancer cells)19 may have influenced their epitope. This evidence concerns the gene MUC1 and breast carcinoma.